Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD5QEL)

Drug Name
PMID28270021-Compound-WO2016054807Example1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic pain MG30 Patented [1]
Neuropathic pain 8E43.0 Patented [1]
Pruritus EC90 Patented [1]
Solid tumour/cancer 2A00-2F9Z Patented [1]
Thymic cancer 2C27 Patented [1]
Cross-matching ID
TTD Drug ID
DMD5QEL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Tropomyosin-related kinase A (TrkA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [3]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [4]
MIM-D3 DMZHN5B Alzheimer disease 8A20 Phase 3 [5]
SNA-120 DMPN314 Plaque psoriasis EA90.0 Phase 2 [6]
CT 327 DMQXL1T Plaque psoriasis EA90.0 Phase 2 [7]
ONO-7579 DMXLPYE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Altiratinib DMUJCBT Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [9]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting NT-3 growth factor receptor (TrkC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [4]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [11]
Altiratinib DMUJCBT Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
PMID28270010-Compound-Figure24-b DM0QHLK N. A. N. A. Patented [8]
Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR Chronic pain MG30 Patented [1]
3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ Chronic pain MG30 Patented [1]
PMID28270010-Compound-Figure5-1 DM2YAPJ N. A. N. A. Patented [8]
PMID28270021-Compound-WO2015042088Example4 DM6KXOQ Chronic pain MG30 Patented [1]
PMID28270010-Compound-Figure5-2 DMK3GRZ N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting BDNF/NT-3 growth factors receptor (TrkB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [4]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [11]
PMID28270010-Compound-Figure24-b DM0QHLK N. A. N. A. Patented [8]
Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR Chronic pain MG30 Patented [1]
3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ Chronic pain MG30 Patented [1]
PMID28270010-Compound-Figure5-1 DM2YAPJ N. A. N. A. Patented [8]
PMID28270021-Compound-WO2015042088Example4 DM6KXOQ Chronic pain MG30 Patented [1]
PMID28270010-Compound-Figure5-2 DMK3GRZ N. A. N. A. Patented [8]
PMID28270010-Compound-Figure5-3 DMSOT1R N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
BDNF/NT-3 growth factors receptor (TrkB) TTKN7QR NTRK2_HUMAN Inhibitor [1]
NT-3 growth factor receptor (TrkC) TTXABCW NTRK3_HUMAN Inhibitor [1]
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [1]

References

1 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
8 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
9 National Cancer Institute Drug Dictionary (drug id 747694).
10 National Cancer Institute Drug Dictionary (drug id 766123).
11 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.